Benfotiamine or standard vitamin B1

Editorial draft: machine-assisted translation of the cited source text. The text was read in full and copyedited. Independent clinical review and source verification are still pending. The statements and amounts given in the source are not individual treatment advice.

How benfotiamine differs from thiamine

Benfotiamine is a synthetic, fat-soluble derivative of thiamine (vitamin B1). It is classified as an S-acyl thiamine compound (a thiamine prodrug carrying an attached benzoyl group that makes it lipid-soluble). After absorption, the body converts it into thiamine. That fat solubility is the key difference: it allows higher thiamine concentrations in tissue per oral dose than standard water-soluble thiamine can reach.

Benfotiamine belongs to the same biochemical family as thiamine, but it behaves differently in the body. S-acyl thiamine derivatives such as benfotiamine are pharmacologically distinct from lipid-soluble thiamine disulfide derivatives such as sulbutiamine and fursultiamine. In the US, benfotiamine is sold as a dietary supplement. In parts of Europe it has been used clinically for some time in connection with diabetic polyneuropathy. Source

Chemistry and the S-acylthiamine family

Benfotiamine’s full chemical name is S-benzoylthiamine monophosphate. It is an open-ring thiamine derivative, and its S-acyl group is what makes it lipid-soluble. After oral intake, intestinal phosphatases cleave off the phosphate group, and benfotiamine is then converted enzymatically into thiamine. This conversion step is well characterized. Sulbutiamine and fursultiamine use different chemical strategies to achieve lipid solubility and have different pharmacological profiles. Synthetic thiamine thioesters, including benfotiamine, are currently being investigated for use in neurodegenerative diseases. Put simply, benfotiamine gets thiamine into tissue more efficiently. Source Source

From development in Japan to use in Europe

Benfotiamine was developed in Japan in the 1950s as part of the allithiamine and S-acylthiamine family, originally aimed at treating thiamine deficiency states. European clinical practice, particularly in Germany, adopted it from the 1990s onward to treat diabetic polyneuropathy. Early clinical use of benfotiamine for diabetic polyneuropathy in Germany is documented from that period. It reached the US market as a dietary supplement in the 2000s. Its regulatory status varies widely by region: clinical use in parts of Europe, availability only as a dietary supplement in the US. B vitamins, including benfotiamine, have been studied in various clinical settings for diabetic pain and neuropathy. Source Source

Mechanism: transketolase and the AGE pathway

The main proposed mechanism of action is activation of transketolase. Benfotiamine raises intracellular levels of thiamine pyrophosphate. This cofactor activates transketolase (an enzyme that diverts excess glucose metabolites away from harmful biochemical pathways). Pharmacokinetics explains why researchers studied benfotiamine rather than standard thiamine in this context. In hyperglycemia, that is, raised blood sugar, this diversion could be relevant.

Polyol, hexosamine and AGE pathways

In hyperglycemic states, excess glucose drives three harmful metabolic pathways: the polyol pathway, the hexosamine pathway and the formation of advanced glycation end products (AGEs). Each contributes to the microvascular and nerve damage seen in diabetes. Benfotiamine blocked all three major pathways of hyperglycemic damage and prevented experimental diabetic retinopathy in animal models. The mechanism: by activating transketolase, excess glucose metabolites are rerouted into the pentose phosphate pathway instead. High-dose thiamine and benfotiamine prevented incipient diabetic nephropathy in animal models through the same intervention in the AGE pathway. This mechanism is well characterized in cell and animal models. It is a mechanistic rationale, not proof of a clinical benefit. How well it carries over to humans is covered in the section on the evidence. Source Source

Pharmacokinetics: absorption, tissue distribution and the bioavailability ceiling

Standard water-soluble thiamine is absorbed through active transport in the gut. This transport system is saturable and limits absorption to about 8 to 15 mg per day, regardless of dose. Benfotiamine bypasses this ceiling by passive diffusion across lipid membranes. At equivalent oral doses, benfotiamine produces higher concentrations of thiamine pyrophosphate in plasma and red blood cells than thiamine HCl. Comparative bioavailability studies of thiamine derivatives confirm this advantage. A pharmacokinetic analysis of multivitamin preparations supports the same conclusion. Clinical trials have studied oral doses of 150 to 600 mg per day, with diabetic neuropathy trials typically at the upper end. The pharmacokinetic advantage over standard thiamine is well described. Whether it leads to correspondingly larger improvements in nerve function is something the studies answer inconsistently. Source Source Source

What human studies show

Claims about benfotiamine fall into four areas, each backed by evidence of different strength: raising tissue thiamine compared with standard thiamine (moderate), symptoms of diabetic peripheral neuropathy (limited and mixed), diabetic nephropathy and markers of vascular function (limited, surrogate endpoints), and cognition in early Alzheimer’s disease (limited, a single small phase IIa trial).

Benfotiamine raises tissue thiamine more than comparable standard doses of thiamine: moderate evidence

A human pharmacokinetic study confirmed higher thiamine pyrophosphate levels in plasma and red blood cells with benfotiamine than with thiamine HCl at equivalent doses. Comparative bioavailability data for various thiamine derivatives back up this finding. PK comparisons in multivitamin preparations add further supporting data. The pharmacokinetic advantage is measurable. Whether it also brings a clinical benefit is a separate and harder question. Source Source Source

Benfotiamine improves symptoms of diabetic peripheral neuropathy: limited evidence

The BEDIP pilot study showed slight improvements in neuropathy scores over three weeks. The randomized controlled BENDIP trial found slight improvements at higher doses. Dose-response data suggest that higher doses lead to marginally better results. The 12-month BOND trial found limited effects on morphometric and neurophysiological measures. A 24-month double-blind RCT in type 1 diabetes found no significant effect on peripheral nerve function. The pattern: short studies show signs of symptom improvement, while longer studies targeting objective nerve-function endpoints produce inconclusive to negative results. Benfotiamine does not appear in standard guidelines for drug treatment of painful diabetic peripheral neuropathy. Symptoms of peripheral neuropathy should be assessed by a doctor. Self-treatment with dietary supplements is no substitute for that assessment. Source Source Source Source Source Source

Benfotiamine improves markers of diabetic nephropathy or vascular function: limited evidence

A 12-week RCT in diabetic nephropathy reported effects on AGE pathway markers without clear differences in clinical outcomes. A follow-up study in the same population showed signs consistent with the described mechanism for AGEs and endothelial dysfunction. A 6-week RCT found effects on postprandial vascular and autonomic function in type 2 diabetes. Preclinical data suggest that benfotiamine protects against peritoneal and kidney damage, although results from animal models can only be applied to humans with caution. These are studies with surrogate endpoints. Confirmation in adequately powered clinical trials is still pending. Source Source Source Source

Benfotiamine improves cognition in early Alzheimer’s disease: limited evidence

A phase IIa RCT found modest cognitive findings in early Alzheimer’s disease, but the trial was small and preliminary. A registered phase 2A/2B trial protocol indicates that research is ongoing but not yet complete. Broader reviews of thiamine derivatives in neurodegenerative diseases provide the mechanistic context for this interest. Research here is still at an early stage. A single small phase IIa trial was not able to establish efficacy. Source Source Source

There is no evidence that benfotiamine adequately treats or cures diabetic neuropathy; standard treatment guidelines do not list it. It does not replace necessary diabetes care, nor does it replace parenteral thiamine in Wernicke-Korsakoff syndrome or acute thiamine deficiency. Use in Alzheimer’s disease is also not yet supported beyond preliminary research. In the acute deficiency states mentioned, parenteral thiamine remains the standard of care. Source

Which form of thiamine is worth considering?

The form matters because the route of absorption is fundamentally different. Standard water-soluble thiamine (thiamine HCl, thiamine mononitrate) is absorbed by active transport in the gut, with saturable kinetics. Benfotiamine bypasses this ceiling through passive absorption across lipid membranes and reaches higher tissue thiamine levels per oral dose. What counts is which form delivers enough thiamine to tissue for the particular use.

Benfotiamine is typically studied at 150 to 600 mg per day in oral capsule form. Standard thiamine HCl is generally supplemented at 50 to 100 mg per day; clinical thiamine deficiency is treated with higher doses or parenteral administration. Other lipid-soluble thiamine derivatives such as sulbutiamine and fursultiamine have different pharmacology and separate bodies of evidence. Given that the compound is synthetic, third-party testing (USP, NSF, ConsumerLab) is a useful pointer to product quality. The label should say “benfotiamine” explicitly, not “thiamine derivative.” Source

Regulatory status of benfotiamine as of May 2026

In the United States, benfotiamine is legally marketed as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA). It is not FDA-approved for any medical indication. Disease claims are not permitted on dietary supplement labels in the US. European sources refer to a different regulatory framework.

Different rules apply in Europe. In Germany and selected other European markets, benfotiamine has a documented history of clinical use for diabetic polyneuropathy in certain treatment settings. Early clinical use of benfotiamine for diabetic polyneuropathy in Europe dates back to the mid-1990s. Clinical commentary on oral benfotiamine for protecting nerves in diabetes reflects this European prescribing tradition. This clinical use in Europe does not translate into FDA approval in the US. These are separate regulatory frameworks, and the difference matters when interpreting European studies. According to the source text, as of May 2026 benfotiamine is not on the World Anti-Doping Agency (WADA) Prohibited List. Source Source

Safety, side effects and drug interactions

Short-term safety is reasonably well described in the European RCTs. Together, the BEDIP, BENDIP, BOND, Fraser and Stirban trials cover durations from 3 weeks to 24 months. Long-term safety data beyond 24 months are limited. For anyone planning long-term use, this data gap is relevant.

Side effects reported in clinical trials

The adverse events most often reported in the published RCT literature are mild and infrequent. Mild gastrointestinal discomfort, headache and occasional skin reactions were described most often. Serious adverse events are rare in the BENDIP trial and related studies. The 12-month BOND trial found no signals of cardiovascular, hepatic or renal toxicity at typical study doses of 150 to 600 mg per day. The compound is generally well tolerated at these doses in the European clinical trials. Source Source Source

Possible drug interactions

• Loop diuretics (furosemide): minor. Theoretical: loop diuretics can increase urinary thiamine loss; the clinical relevance of additional benfotiamine is not well established.

• 5-fluorouracil chemotherapy: theoretical / moderate. 5-FU can inhibit thiamine activation; the clinical relevance of additional benfotiamine during cancer treatment needs to be judged by a doctor.

• Other blood-sugar-lowering supplements. Minor. No documented additive glycemic effect; benfotiamine’s mechanism of action concerns damage from glucose metabolites, not lowering glucose levels.

Pregnancy, breastfeeding and special populations

Taking additional benfotiamine during pregnancy and breastfeeding has not been adequately studied at the doses used in clinical trials. Although the standard thiamine requirement rises during pregnancy, it has not been established whether additional benfotiamine at these doses is safe. It is generally avoided without medical guidance. Liver and kidney impairment have not been studied extensively; thiamine pyrophosphate is excreted by the kidneys, which matters when kidney function is reduced. Pediatric use is not described in the published literature.

When to get medical advice before taking it

Some groups need medical advice before taking benfotiamine: pregnancy and breastfeeding (no safety data for supplemental doses), people with diabetic peripheral neuropathy who are looking for treatment (not in the guidelines), suspected thiamine deficiency due to alcohol dependence or an eating disorder (parenteral thiamine remains the standard treatment), active 5-FU chemotherapy without clearance from the oncology team, and children.

• Pregnant or breastfeeding people: no controlled human safety data for supplemental doses.

• People with diabetic peripheral neuropathy who are looking for treatment: benfotiamine is not included in standard guidelines for drug treatment of diabetic neuropathy; an endocrinology or neurology assessment is needed. Source

• People with suspected thiamine deficiency due to alcohol dependence or an eating disorder: parenteral thiamine is the standard treatment; benfotiamine is not a substitute.

• Active 5-FU chemotherapy without clearance from the oncology team: theoretical interaction.

• Children: there are not enough data on supplemental doses in children.

If any of these apply, get medical advice before taking it. A complete list of medications and any existing lab results belong in that assessment.

Benfotiamine vs. standard thiamine

In comparing the two, what counts is which form delivers enough thiamine to tissue for the particular use.

• Source / chemistry. Benfotiamine: synthetic S-acylthiamine prodrug; fat-soluble. Standard thiamine: water-soluble thiamine HCl or thiamine mononitrate; the native vitamin form.

• Bioavailability. Benfotiamine: passive absorption across lipid membranes; bypasses the saturable active-transport ceiling of standard thiamine. Standard thiamine: saturable active transport limits absorption to about 8 to 15 mg per day. Source

• Best-supported effects. Benfotiamine: European diabetic neuropathy trials show slight symptom improvements over 3 weeks and moderate improvements at higher doses; longer trials show limited effects on nerve function at 12 months and no significant effect at 24 months in type 1 diabetes; the Alzheimer’s evidence is limited to a single phase IIa trial. Standard thiamine: standard treatment for Wernicke-Korsakoff syndrome (parenteral) and thiamine deficiency syndrome; broader data on thiamine in diabetes from a systematic review. Source Source Source Source Source Source

• Dose range studied. Benfotiamine: 150 to 600 mg per day in oral RCTs. Standard thiamine: 50 to 100 mg per day for general supplementation; 100 to 500 mg per day or parenteral for clinical deficiency.

• Key safety differences. Benfotiamine: mild gastrointestinal discomfort, headache and occasional skin reactions in trials. Standard thiamine: well-characterized safety profile; the parenteral form occasionally causes hypersensitivity reactions.

• Cost (relative). Benfotiamine: $$. Standard thiamine: $.

• Regulatory status. Both: dietary supplements in the US under DSHEA as of May 2026. Standard thiamine: clinical use as a medicine for deficiency states. Benfotiamine: long clinical use in some European markets; available only as a dietary supplement in the US.

For thiamine deficiency due to alcohol dependence or an obvious nutrient deficiency, parenteral or oral standard thiamine has the stronger evidence base and the better regulatory standing. For research on the AGE pathway and on how diabetic complications develop, benfotiamine is the more relevant comparator. Studies on clinical outcomes remain mixed, however. To track changes, the source text names the biomarkers HbA1c, fasting glucose, hs-CRP and homocysteine, measured at the start and again after 12 weeks, each time at the same lab and under the same morning conditions. If there are symptoms of peripheral neuropathy, the next step is a medical assessment, whether or not benfotiamine is being considered.

What to measure before and after 12 weeks

A subjective sense of improvement on its own is not reliable proof that something works. The relevant signals come from blood tests and, for neuropathy specifically, from a doctor’s clinical assessment of nerve function.

• HbA1c: average blood sugar exposure over three months; benfotiamine is proposed to dampen the upstream driver of the AGE, polyol and hexosamine pathways.

• Fasting glucose: current blood sugar level. Benfotiamine’s mechanism targets damage downstream of hyperglycemia, not the lowering of blood sugar itself.

• hs-CRP: an indirect marker of AGE and inflammatory pathway activity, given that clinical AGE-RAGE tests are not widely available.

• Homocysteine: relevant in the broader context of B-vitamin neuropathy; thiamine status interacts with B6 and B12 status. Source

• Thiamine (whole-blood TPP), where available: a direct marker of thiamine status; test availability varies by lab.

• Clinical nerve conduction testing: not a blood biomarker but a medical examination for assessing neuropathy; benfotiamine is no substitute for a clinical examination.

Collecting these baseline values before starting benfotiamine (or any new supplement) gives objective reference points that make any later change interpretable. Without a baseline, a response cannot be told apart from regression to the mean or a placebo effect. If neuropathy symptoms are the reason for considering it, the medical examination should determine the next step.

Why neuropathy symptoms need a medical assessment

Suspected diabetic peripheral neuropathy, for instance with burning, tingling, numbness, weakness or changes in gait, calls for a medical assessment. The right starting point is an endocrinology or neurology consultation with nerve conduction studies and a full diabetes workup. Benfotiamine does not appear in guidelines on standard drug treatment for diabetic peripheral neuropathy, so any plan to take it should be discussed with a doctor. Source

The mechanism is well described, but the clinical results remain mixed. That is why reliable baseline measurements and a medical assessment matter, regardless of whether benfotiamine later becomes part of treatment.

Frequently asked questions

What is benfotiamine?

Benfotiamine is a synthetic, fat-soluble S-acyl derivative of thiamine (vitamin B1): a prodrug that the body converts into thiamine. It reaches higher tissue thiamine levels than comparable doses of water-soluble thiamine. Source

What is benfotiamine used for?

Benfotiamine has been studied in clinical trials for diabetic peripheral neuropathy, with mixed results. It is not included in standard guidelines for drug treatment of this condition. Benfotiamine has also been studied in Alzheimer’s disease in preliminary phase IIa trials. Source Source

What does benfotiamine do in the body?

Benfotiamine activates transketolase, an enzyme that diverts glucose metabolites away from harmful biochemical pathways, including the polyol pathway, the hexosamine pathway, PKC activation and AGE formation. This mechanism explains the research interest in diabetic complications. Whether it translates into clinically meaningful nerve-function outcomes in humans, however, remains an open research question. Source

Is benfotiamine a vitamin, a mineral or an herbal product?

Benfotiamine is a synthetic vitamin derivative, specifically an S-acyl prodrug of thiamine (vitamin B1), and not a vitamin, mineral or herbal product in its own right. It is sold in the US as a dietary supplement under DSHEA, while in Europe it has been used in clinical practice for diabetic neuropathy for decades.

Where does benfotiamine come from?

Benfotiamine is a synthetic derivative of thiamine, first developed in Japan in the 1950s as part of the family of allithiamine and S-acyl thiamine derivatives. Unlike thiamine, which occurs naturally in whole grains, legumes, pork and fortified foods, benfotiamine does not occur naturally in food. Modern benfotiamine is made by chemical synthesis and given as oral capsules at typical doses of 150 to 600 mg/day.

How does benfotiamine compare with standard thiamine?

Benfotiamine is fat-soluble and passes through cell membranes more easily than standard thiamine, so it reaches higher tissue thiamine levels at equivalent doses. It remains unclear, however, whether this leads to clinically meaningful differences in the course of diabetic complications. For correcting thiamine deficiency in conditions such as alcohol dependence or Wernicke-Korsakoff syndrome, standard parenteral thiamine remains the standard of care. Source

Does benfotiamine really work?

Research has studied benfotiamine in diabetic neuropathy with mixed results. Some studies showed moderate improvements in neuropathy scores, while others found limited or no significant effects on nerve function. Benfotiamine is not included in US or European treatment guidelines for neuropathy. Source Source

Is benfotiamine available as a dietary supplement?

Yes: as of May 2026, benfotiamine is legally marketed in the US as a dietary supplement under DSHEA. It is not FDA-approved for any indication, although it has long been used clinically for diabetic neuropathy in some European markets. Benfotiamine is not on the WADA Prohibited List.

Sources

• Volvert ML, Seyen S, Piette M, Evrard B, Gangolf M, Plumier JC, Bettendorff L (2008). Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC pharmacology, 8, 10. https://doi.org/10.1186/1471-2210-8-10 Source

• Bettendorff L (2023). Synthetic Thioesters of Thiamine: Promising Tools for Slowing Progression of Neurodegenerative Diseases. International journal of molecular sciences, 24(14). https://doi.org/10.3390/ijms241411296 Source

• Stracke H, Lindemann A, Federlin K (1996). A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 104(4), 311-6. https://doi.org/10.1055/s-0029-1211460 Source

• Karaganis S, Song XJ (2021). B vitamins as a treatment for diabetic pain and neuropathy. Journal of clinical pharmacy and therapeutics, 46(5), 1199-1212. https://doi.org/10.1111/jcpt.13375 Source

• Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M (2003). Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nature medicine, 9(3), 294-9. https://doi.org/10.1038/nm834 Source

• Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ (2003). Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes, 52(8), 2110-20. https://doi.org/10.2337/diabetes.52.8.2110 Source

• Xie F, Cheng Z, Li S, Liu X, Guo X, Yu P, Gu Z (2014). Pharmacokinetic study of benfotiamine and the bioavailability assessment compared to thiamine hydrochloride. Journal of clinical pharmacology, 54(6), 688-95. https://doi.org/10.1002/jcph.261 Source

• Greb A, Bitsch R (1998). Comparative bioavailability of various thiamine derivatives after oral administration. International journal of clinical pharmacology and therapeutics, 36(4), 216-21. https://pubmed.ncbi.nlm.nih.gov/9587048/ Source

• Park WS, Lee J, Hong T, Park G, Youn S, Seo Y, Lee S, Han S (2016). Comparative Pharmacokinetic Analysis of Thiamine and Its Phosphorylated Metabolites Administered as Multivitamin Preparations. Clinical therapeutics, 38(10), 2277-2285. https://doi.org/10.1016/j.clinthera.2016.08.009 Source

• Haupt E, Ledermann H, Köpcke W (2005). Benfotiamine in the treatment of diabetic polyneuropathy–a three-week randomized, controlled pilot study (BEDIP study). International journal of clinical pharmacology and therapeutics, 43(2), 71-7. https://doi.org/10.5414/cpp43071 Source

• Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG (2008). Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 116(10), 600-5. https://doi.org/10.1055/s-2008-1065351 Source

• Winkler G, Pál B, Nagybéganyi E, Ory I, Porochnavec M, Kempler P (1999). Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy. Arzneimittel-Forschung, 49(3), 220-4. https://doi.org/10.1055/s-0031-1300405 Source

• Bönhof GJ, Sipola G, Strom A, Herder C, Strassburger K, Knebel B, Reule C, Wollmann JC, Icks A, Al-Hasani H, Roden M, Kuss O, Ziegler D (2022). BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy. BMJ open, 12(2), e057142. https://doi.org/10.1136/bmjopen-2021-057142 Source

• Fraser DA, Diep LM, Hovden IA, Nilsen KB, Sveen KA, Seljeflot I, Hanssen KF (2012). The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. Diabetes care, 35(5), 1095-7. https://doi.org/10.2337/dc11-1895 Source

• Waldfogel JM, Nesbit SA, Dy SM, Sharma R, Zhang A, Wilson LM, Bennett WL, Yeh HC, Chelladurai Y, Feldman D, Robinson KA (2017). Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: A systematic review. Neurology, 88(20), 1958-1967. https://doi.org/10.1212/WNL.0000000000003882 Source

• Alkhalaf A, Klooster A, van Oeveren W, Achenbach U, Kleefstra N, Slingerland RJ, Mijnhout GS, Bilo HJ, Gans RO, Navis GJ, Bakker SJ (2010). A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes care, 33(7), 1598-601. https://doi.org/10.2337/dc09-2241 Source

• Alkhalaf A, Kleefstra N, Groenier KH, Bilo HJ, Gans RO, Heeringa P, Scheijen JL, Schalkwijk CG, Navis GJ, Bakker SJ (2012). Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy. PloS one, 7(7), e40427. https://doi.org/10.1371/journal.pone.0040427 Source

• Stirban A, Pop A, Tschoepe D (2013). A randomized, double-blind, crossover, placebo-controlled trial of 6 weeks benfotiamine treatment on postprandial vascular function and variables of autonomic nerve function in Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 30(10), 1204-8. https://doi.org/10.1111/dme.12240 Source

• Kihm LP, Müller-Krebs S, Klein J, Ehrlich G, Mertes L, Gross ML, Adaikalakoteswari A, Thornalley PJ, Hammes HP, Nawroth PP, Zeier M, Schwenger V (2011). Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis. Journal of the American Society of Nephrology : JASN, 22(5), 914-26. https://doi.org/10.1681/ASN.2010070750 Source

• Gibson GE, Luchsinger JA, Cirio R, Chen H, Franchino-Elder J, Hirsch JA, Bettendorff L, Chen Z, Flowers SA, Gerber LM, Grandville T, Schupf N, Xu H, Stern Y, Habeck C, Jordan B, Fonzetti P (2020). Benfotiamine and Cognitive Decline in Alzheimer’s Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial. Journal of Alzheimer’s disease : JAD, 78(3), 989-1010. https://doi.org/10.3233/JAD-200896 Source

• Feldman HH, Luchsinger JA, Léger GC, Taylor C, Jacobs DM, Salmon DP, Edland SD, Messer K, Revta C, Flowers SA, Jones KS, Koulman A, Yarasheski KE, Verghese PB, Venkatesh V, Zetterberg H, Durant J, Lupo JL, Gibson GE, ADCS BenfoTeam Study Group (2024). Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer’s disease (BenfoTeam). PloS one, 19(5), e0302998. https://doi.org/10.1371/journal.pone.0302998 Source

• (2004). [Oral benfotiamine therapy. Thus you protect the nerves of diabetic patients]. MMW Fortschritte der Medizin, 146(5), 52-3. https://pubmed.ncbi.nlm.nih.gov/15035429/ Source

• Muley A, Fernandez R, Green H, Muley P (2022). Effect of thiamine supplementation on glycaemic outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. BMJ open, 12(8), e059834. https://doi.org/10.1136/bmjopen-2021-059834 Source